Generex Biotechnology Corporation announced it would stage the Phase I trial of its cancer immunotherapy in China. The trial will be performed in collaboration with Dr. Daopei Lu and the Beijing Daopei Hospital in Beijing, China. The immunotherapy demonstrated a robust anti-tumor immunity in a variety of mouse tumor models. More details...

Stock Symbols: (NSDQ: GNBT)